Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670074 | 0.86 | KMT2A (0.39) | RAB9AESR1MMP2KMT2A | |
| SCHEMBL32669930 | 0.85 | RAB9A (0.38) | RAB9AESR1SLC22A12MMP2MEN1 | |
| SCHEMBL32669648 | 0.84 | KMT2A (0.51) | RAB9AESR1MEN1KMT2A | |
| SCHEMBL32670060 | 0.81 | COMT (0.43) | SLC22A12 | |
| SCHEMBL32669777 | 0.79 | SLC22A12 (0.43) | SLC22A12MEN1KMT2A | |
| SCHEMBL30740965 | 0.78 | FTO (0.62) | RAB9AMEN1KMT2A | |
| SCHEMBL32669597 | 0.78 | ESR1 (0.38) | RAB9AESR1KMT2A | |
| SCHEMBL32669956 | 0.76 | COMT (0.55) | SLC22A12MEN1KMT2A | |
| SCHEMBL32669921 | 0.75 | SCN9A (0.45) | RAB9AMEN1KMT2A | |
| SCHEMBL32669611 | 0.75 | ALDH1A1 (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | RAB9A 3162/4885ESR1 1076/4885SLC22A12 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.